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Intrauterine Device Initiation Following Gonoccocal and Chlamydial Infections:
A Practice Workflow Initiative
Abstract
Background: Unplanned pregnancy remains an issue in the United States. The intrauterine
device (IUD) is a solution. The IUD is safe for most women and is recommended for
adolescents. Misconceptions exist around IUDs and sexually transmitted infections (STIs)
caused by Neisseria gonorrhoeae and Chlamydia trachomatis. Accepted guidelines ensure the
management of these STIs and subsequent, safe initiation of the IUD.
Methods: The use of best practice alerts preserves the healthcare team’s adherence to clinical
guidelines.
Conclusion: This IUD provision initiative creates a workflow for the interprofessional team to
ensure the safe initiation of an IUD to clients with a gonoccocal or chlamydial infection.
Keywords: intrauterine devices, long-acting reversible contraception, unplanned pregnancy,
sexually transmitted diseases, Neisseria gonorrhoeae, Chlamydia trachomatis, workflow, quality
improvement, best practice alerts, clinical decision-making
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Intrauterine Device Initiation Following Gonoccocal and Chlamydial Infections:
A Practice Workflow Initiative

Introduction
To combat the persistently high rate of unplanned pregnancy in the United States, the
Healthy People 2020 objectives appeal for the endowment of highly effective contraception.1
Accessible long-acting reversible contraception (LARC), including the intrauterine device (IUD)
and the subdermal implant, can meet this goal. The unplanned pregnancy rate is highest for
those under the age of 25.2 Women under age 25 are at the highest risk for the sexually
transmitted infections (STI), N. gonorrhoeae (NG) and C. trachomatis (CT).3 Although the
presence of a known or suspected gonoccocal or chlamydial infection is a contraindication to
IUD initiation, the IUD may be safely inserted after the infection is cured.3 Adherence to these
IUD best practices by some healthcare providers is lacking and limits IUD provision.4,5 The lack
of compliance to IUD best practices creates an interruption in contraception management.
Employing electronic health record (EHR) generated best practice alerts (BPAs) can safeguard
the healthcare team’s adherence to clinical guidelines. Improving the adherence to evidencebased IUD best practices, relative to gonococcal or chlamydial infections, supports the goal to
decrease unplanned pregnancies. The goal of this article is to present a clinical practice initiative,
using BPAs, to preserve the safe provision of an IUD to clients seeking IUD initiation, following
the diagnosis of a gonococcal or chlamydial infection.
The management of the IUD relative to a gonococcal or chlamydial infection is well
documented.3 Inconsistent adherence to this management may impair IUD provision. In a
clinical example, a client requesting an IUD is found to have a chlamydial infection after STI
screening and the forthcoming IUD insertion appointment is canceled despite the infection being
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resolved.6 In this example, the client goes without highly reliable contraception. The electronic
health record (EHR) can facilitate the healthcare team’s workflow, adherence to IUD best
practices, and client-centered goal of IUD initiation. Employing a computer-based workflow,
such as best practice alerts, for the interprofessional healthcare team can optimize clinical
decision-making and patient outcomes.7 The World Health Organization (WHO) recommends a
task sharing approach to optimize family planning services using a team-based model.8 This
IUD provision initiative uses Lewin’s Theory of Planned Change to mobilize the healthcare team
in its adoption.9 The use of BPAs in this IUD provision initiative can prevent missed or delayed
diagnosis and treatment of STIs and thwarted IUD provision. By implementing this IUD
provision initiative, the healthcare team can ensure that appropriate contraception is safely
provided.
Background and Significance
Approximately 45% of all pregnancies in the United States are unplanned.2 Women less
than age 25 have higher rates of contraception failure, unplanned pregnancy, and pregnancyrelated morbidity, compared to older clients.10 The IUD is a safe, highly effective LARC that
can decrease the unplanned pregnancy rate.11 As LARC, the IUD is a, “set it and forget it”
method for three to ten years, duration varies by the type of IUD. Although LARC is more
effective than other types of birth control methods, with a failure rate of less than one percent, it
remains underutilized.12,13 Adherence to IUD best practices by some healthcare providers is
lacking and limits IUD provision.4,5 Bias against IUD use, by some healthcare providers and the
public, restricts its utilization, manifested by an overall use of 11.8% in the United States.14
Healthcare provider adherence to IUD best practices can be optimized with the use of
EHR-generated best practice alerts (BPAs). These BPAs, as a clinical decision-support system,
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have shown to significantly improve outcomes in preventative healthcare practices including the
prescription of appropriate, timely treatment therapies.15
Underutilization Due to Lack of Knowledge
In regards to IUD use and STIs, two dominant themes are evident. The first theme is the
lack of knowledge perpetuated by misconceptions, fears, and biases of some healthcare providers
and the public. Research demonstrates that some healthcare providers are reluctant to use the
IUD out of fear of complications, such as pelvic inflammatory disease (PID).16,17 This bias is
due to a memory of an older generation of IUDs, such as the Dalkon Shield in the 1970s, that led
to these complications. The current generation of IUDs is deemed safe for most women.17 In a
landmark study to assess provider IUD knowledge, Kohn et al. identified barriers to IUD
provision and assessed the likelihood of provider recommendation of the IUD to adolescents.18
The study surveyed 162 employees of New York City school based health centers (SBHC). The
SBHC team included healthcare providers, health educators, social workers, nurses, medical
assistants, and receptionists. Misconceptions and misinformation on client eligibility for the IUD
were isolated as barriers and restricted provision of the IUD. Most of the SBHC team would not
recommend the IUD to clients with a remote or recent history of a STI, PID, or if they were nonmonogamous. Lastly, this sentinel study found that the risk of STIs was a barrier to IUD
recommendation by SBHC providers.18 A recent study elucidates women’s healthcare provider
beliefs in the IUD and found statistically significant increases in IUD beliefs and usage after an
educational intervention on IUD best practices, including IUD initiation after a gonococcal or
chlamydial infection.19
Likewise, the public’s lack of access to and information on the IUD creates
underutilization.20,21 A perceived lack of control and autonomy, often due to historical
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contraceptive coercion, have been cited by some women as barriers to IUD use.21,22 These
attitudes are exceptionally well-defined in the Black and Latina populations who possess the
highest rates of unplanned pregnancy.2,22 It is imperative that women receive access to reliable
contraceptive counseling and provision, relevant to their needs. Shared contraceptive decisionmaking and consistency of LARC counseling need improvement.23 Comprehensive,
nonjudgmental, informed consent for contraceptive care can decrease barriers to use.
Safety of the IUD and Sexually Transmitted Infections
The second theme pertaining to IUD underutilization is the safety of the IUD, particularly
related to STIs. The safety of the IUD and its relationship to STIs is well studied since routine
screening for gonococcal and chlamydial infections is recommended before initiation.3 The IUD
has relatively few contraindications and is deemed safe for all age groups regardless of STI
history.3 C. trachomatis is the most common STI and one of the possible causes of PID.3
Studies have found that the rate of complications, such as PID, is less than one percent for all
types of IUDs and age groups.24, 25 The overall lifetime risk of PID is 4.4%.25 Drake et al.
studied a high-risk population of IUD users (N=283) and found that 49.5% had a history of a STI
and a rate of PID of 0.7%, at 12 months of IUD use.25 This study supports the safety of IUDs
and that its use should not be restricted due to the fear of STIs.25 The ongoing education of the
healthcare team and the public can facilitate IUD provision.19, 26 The translation of evidencebased guidelines into clinical practice can be reinforced by using EHR-generated best practice
alerts. This paper presents a workflow strategy for IUD provision to clients desiring IUD
initiation who test positive for N. gonorrhoeae and C. trachomatis.
Methods
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The literature was reviewed on IUDs, STIs, clinical practice workflow, clinical decision
support systems, and best practice alerts (BPA). Clinical decision support systems, such as
BPAs, are created in the EHR to notify the healthcare team of serious events like abnormal
results and needed follow-up. The research on evidence-based IUD and STI guidelines and
BPAs were examined to develop the IUD initiative workflow. The CDC guidelines on IUDs and
STIs serve as the foundational clinical resource for this workflow.3,16 As a clinical decision
support system, BPAs are user-friendly and functional. Best practice alerts prompt the healthcare
team to identify and treat a gonoccocal and/or chlamydial infection and confirm that the IUD
insertion is scheduled appropriately.
Motivating the healthcare team to change their current workflow can be challenging.
Consistent with the barriers to IUD utilization, barriers to organizational productivity include
individual biases that can create conflicts among the team.28 Lewin’s Theory of Planned Change
(Lewin) crafts the framework for the organizational modifications necessary to adopt the IUD
initiative.9 Lewin’s theory expedites the exploration of the organizational factors related to
barriers to IUD provision. Factors such as healthcare team member biases and misconceptions
about IUDs and STIs are explored in Lewin’s first stage of change, unfreezing. Lewin’s second
stage, transitioning, represents the active workflow modifications that the team executes as they
begin the initiative. Lewin’s third and final stage, refreezing, solidifies the changes, and
establishes the workflow sustainability.9
Results
Unfreezing
The goal of this clinical practice initiative is to safeguard the safe provision of an IUD to
clients requesting IUD insertion who screen positive for a gonococcal or chlamydial infection.
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To implement the initiative, modifications in the organization’s workflow require preparation
and buy-in from the team. Lewin’s theory describes this stage as unfreezing.9 In this first stage,
the interprofessional team meets to discuss the problem, review the research on IUDs, STIs, and
workflow practices, and offer solutions. The entire health care team, including reception staff,
information technology (IT), nursing, medical assistants, and providers (nurse practitioners,
midwives, physicians, physician assistants), works collaboratively. A project champion is
selected to lead and evaluate the initiative. The team agrees on the resources that will be used to
guide IUD best practices. In this case, current CDC STI guidelines and IUD recommendations
may be embraced for reference.3,6,16 Next, the team reviews the advantages and disadvantages of
adopting the workflow strategy using best practice alerts (BPA). This workflow is adopted by the
healthcare team to promote the adherence of IUD and STI best practices and protects the
provision of highly effective contraception. Engaging all the members of the healthcare team
ensures a successful first step.
Transitioning
The second step in Lewin’s model, transitioning, encourages the staff to actively engage
in making the necessary workflow changes to ensure that the clinical guidelines and BPAs are
followed.9 Team member roles are defined by the project champion. An expert on IUD and STI
best practices, such as a provider or nurse, conducts this education for the interprofessional team.
The IT department educates on the BPA process. Education is provided at weekly staff meetings
in the two weeks leading up to the implementation. Together, the team considers the types of
BPAs to institute and what they would like flagged. The IT department is crucial in this
execution. The IT department creates the suggested BPAs to alert the team that, 1). a client,
scheduled for an IUD insertion, tests positive for a gonoccocal and/or chlamydial infection, 2).
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proper STI treatment is initiated within 72 hours, and 3). the IUD insertion appointment is
scheduled at least one week after treatment. The BPAs also alert the team when a client misses
the IUD insertion appointment, initiating a phone call (computerized or human) to reschedule the
IUD insertion. The transition from planning to engaging the changes completes this step in the
initiative (see Table 1).
Refreezing
The final stage in Lewin’s theory, refreezing, commences as the team executes the new
workflow.9 The team members assigned workflow roles are resources for the team throughout
the implementation. Periodic audits of the BPAs and workflow validate its use and the reliability
of the technology. Likewise, IUD and STI best practices are reviewed for currency. For
instance, the CDC updates the STI guidelines every five years. When there is a change in the
clinical practice guidelines, the workflow will be modified to reflect this update. Refreezing
supports the initiative’s sustainability. Each team member engages in the process to solidify the
workflow and create a new standard of care.9
In addition to the updating of clinical best practices over time, the evaluation of this
practice initiative is recommended. A query by diagnosis codes for gonoccocal and chlamydial
infection and IUD insertion enables the confirmation of appropriate treatment and successful
IUD insertion (see Table 1). In the treatment of the STIs, a target goal of 100% is necessary to
confirm that the clients are treated appropriately. For the IUD provision, a goal of 70-90% is
optimal to ensure clients that request an IUD had a scheduled insertion appointment and IUD
successfully placed. Patient satisfaction is another measure to consider in the evaluation process.
Surveys exploring patient satisfaction of their contraceptive and STI counseling and IUD
insertion can identify strengths in the IUD provision initiative and opportunities for
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improvement. Evaluation data are shared with the interprofessional team during regularly
scheduled office meetings. The team-based appraisal of the IUD provision initiative promotes its
sustainability.
Discussion
To address the unplanned pregnancy rate of 45% in the US, this IUD provision initiative
can prevent missed opportunities for safe IUD insertions.2 This initiative mobilizes the
healthcare team to adopt BPAs, which promote IUD and STI best practices, prompting the
treatment of STIs and successful IUD insertions. It is imperative to address IUD misconceptions
through the education on IUD and STI best practices. Employing Lewin’s theory generates
proactive collaboration among the team to change the office workflow. Team members are
assigned roles to execute the workflow and evaluate the initiative. Ongoing evaluation of the
workflow’s use of BPAs, timeliness of STI treatment, rate of IUD insertions, and patient
satisfaction is expected. This IUD practice initiative pursues the improvement of safe IUD
provision to clients seeking IUD initiation, following the diagnosis of a gonococcal or
chlamydial infection.
Relevance to Clinical Practice
Research has shown high patient satisfaction and exemplary effectiveness of the IUD,
particularly in the adolescent and young adult population.29 The appropriate education of the
interprofessional healthcare team and the public is paramount for the utilization of the IUD and
can decrease unplanned pregnancy.4 To begin the initiative, the team shares their biases and
knowledge of IUDs and STIs. The team’s unfreezing of personal beliefs and biases allows for
change as they are educated on the current IUD and STI evidence. The educated healthcare team
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provides thorough, individualized client counseling, particularly related to complications, which
can decrease barriers.
Consistent contraceptive counseling and screening for STIs provides safety and
confidence for clients. It is recommended to screen for N. gonorrhoeae and C. trachomatis for
clients at high risk, such as those under age 25, before an IUD insertion. Clients at low risk may
be screened at the time of the IUD insertion.3 The initiation of an IUD is contraindicated with an
active or suspected genital infection, like gonococcal or chlamydial infections.16 Prompt
identification and treatment of gonococcal or chlamydial infections can prevent complications,
such as PID. The insertion of the IUD may proceed after the infection is cured, or one week
after treatment.3 Although the IUD is inserted and removed by a healthcare provider, a client
may have the IUD removed whenever it is desired. There may be a misconception that the IUD
must remain in place for the entire duration of use. Reinforcing that the IUD may be removed at
any time can promote a sense of control for the client. Individualizing contraceptive care, based
on sound clinical decision-making, optimizes the delivery of the appropriate care. This initiative
provides an efficient workflow to ensure the safe provision of highly effective IUD
contraception.
Safeguarding IUD initiation can be expedited by the use of automated BPAs in the EHR.
The acceptance of clinical decision support systems, as BPAs, are designed to promote proficient
patient care, adherence to clinical guidelines, and serve as computerized quality assurance
measures.30,31 The team decides on the types of BPAs and how to use them in the EHR
workflow. Long et al. identify that nurses prefer pop-up alerts to flag that an abnormal finding or
assessment is recorded, which precipitates the next steps.32 The way in which the BPAs notify
the team can be modified as the workflow progresses. For instance, the team chooses that the
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EHR will initiate a pop-up BPA when a positive chlamydial result is obtained. This provokes
the medication order to be generated. In the case of a chlamydial infection, in the absence of
allergies, a one-time dose of azithromycin 1 gram by mouth is generated.3 Next, the nurse
notifies the provider who authorizes the treatment. Once treatment has been prescribed, another
BPA corroborates that the IUD insertion appointment is scheduled appropriately, at least one
week after medication administration. Relative to these STIs, medication compliance is deemed
high since both are treated in a one-time dose, chlamydia orally and gonorrhea as an
intramuscular injection of 500 mg of ceftriaxone administered by the healthcare professional.3 A
final BPA is triggered if the client misses the IUD insertion appointment. The workflow can be
programmed to identify unique client variables such as medication allergies. This quality
assurance measure guides the appropriate STI treatment for each client. Nurses prefer technology
that assists in providing safe and effective care individualized to the patients.32 Best practice
alerts, agreed upon by the team and configured by the IT staff, ensure the expeditious treatment
of STIs and safe provision of the IUD.
Unplanned pregnancy remains a problem in the US. A solution is the improved
utilization of LARC, including the IUD. This IUD provision initiative establishes a workflow to
support this goal. Employing Lewin’s theory, the interprofessional team confronts biases and
misinformation about the IUD and STIs and educates each other on best practices. Empowered
with accurate data, the team executes best practices through the use of BPAs as quality assurance
measures. Community health centers, private offices, and institutions may enable this workflow
to streamline or replace their contraceptive care protocols. After its implementation, the
evaluation of the workflow, clinical outcomes, and patient satisfaction can assess whether the
goals of the initiative and population served are being met using the SQUIRE 2.0 guidelines.33
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This IUD provision initiative enables the healthcare team to validate that highly effective
contraception is safely provided. Facilitating access to safe, reliable contraception can decrease
unplanned pregnancies.
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Table 1. Intrauterine Device Provision Workflow
1. Goal: To increase the provision of the intrauterine device (IUD) to eligible clients who
test positive for N. gonorrhoeae (NG) and C. trachomatis (CT), thereby decreasing the
unplanned pregnancy rate.
Objective

Activities

Timeframe

Responsible Team
Member

Outcomes

A. Adopt clinical
practice
guidelines for
clients with
positive
gonoccocal (NG)
and/or
chlamydia (CT)
result preceding
an IUD
insertion.

1. Educate and
agree upon best
practice
guidelines to
execute the IUD
provision
initiative. 1,2,3

Within one
month

Healthcare team:
receptionists,
medical assistants,
nurses, IT staff,
and providers
(nurse
practitioners,
midwives,
physicians,
physician
assistants)

1. Clinical
practice
guidelines for
IUD provision
are adopted and
instituted as
office policy
within one
month.

2. Notify and
treat the client
of the positive
result according
to CDC
guidelines and
allergy status.

Within 72 hours
of a positive
result

Nursing staff (RN
or LPN), as
authorized by the
provider, provider

2. 100% of
clients with a
positive NG or
CT result will be
notified and
treated.

3. Document the Immediately
Nursing staff,
treatment of
upon notification provider
partner(s)
referral or
treatment.
4. Confirm IUD
placement
appointment is
booked to
ensure safe yet
timely insertion.

Insertion visit is
scheduled at
least one week
after STI
treatment,
ideally within
two weeks of the
counseling visit.

3. 100% of
partner(s)
notification is
documented.

Nursing, reception, 4. 100% of
or medical assistant clients have an
IUD insertion
appointment
booked at least
one week after
treatment.
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Objective

Activities

Timeframe

Responsible Team
Member

Outcomes

B. Develop best
practice alerts
(BPA) to ensure
the desired IUD
insertion.

1. Collaborate
with the IT team
to develop
BPAs notifying
staff that:

Within one
month of initial
team meeting

Project champion,
IT staff

1. Within one
month, active
BPAs notify
staff that:

a). a client,
scheduled for an
IUD insertion,
tests positive for
a gonoccocal
and/or
chlamydial
infection,

a). a client,
scheduled for an
IUD insertion,
tests positive for
a gonoccocal
and/or
chlamydial
infection,

b). proper
treatment of
infection is
initiated within
72 hours,

b). proper
treatment of
infection is
initiated within
72 hours,

c). IUD
insertion
appointment is
scheduled at
least one week
after treatment,

c). IUD insertion
appointment is
scheduled at
least one week
after treatment,

d). IUD
insertion
appointment
was missed
triggering a
follow up call to
reschedule.

d). IUD insertion
appointment was
missed triggering
a follow up call
to reschedule.

2. Goal: Evaluate client outcomes and satisfaction pertaining to the prompt treatment of a
sexually transmitted infection and safe, effective contraception via IUD placement.
Objectives

Activities

Timeframe

Responsible Team
Member

Outcomes

A. Improve
client outcomes
by the prompt
treatment of a
gonoccocal
(NG) and/or
chlamydial (CT)
infection.

1. Conduct an
electronic health
record (EHR)
query for positive
NG/CT results
and prescribed
treatment
following
initiation of
workflow BPAs.

Beginning two
weeks after
implementation
of the initiative

Project champion,
nursing staff

1. One month
after
implementation,
EHR query will
reveal that 100%
of clients with a
positive NG/CT
result will be
prescribed
treatment.

B. Improve
client outcomes
as evidenced by
successful IUD
insertion.

1. Conduct a
billing code
query of IUD
insertions
following the
clinical practice
initiative
initiation.

Monthly for 3
months, then
every 6 months

Project champion

1. One month
after
implementation,
EHR review will
reveal that 7090% of clients
will have an IUD
inserted.

C. Evaluate
client
satisfaction of
their
contraception
and infection
counseling,
treatment, and
IUD insertion.

1. Create a client
satisfaction
survey on
contraception and
infection
counseling,
treatment, and
IUD insertion.

Within one
month of
initiative launch

Project champion,
nursing, providers

1. Client
satisfaction
survey created
and implemented
one month after
initiative started.

2. Distribute
satisfaction
survey at the time
of counseling and
insertion visits.

One month after
initiative launch
and ongoing

Nursing,
receptionist,
medical assistant

2. 100% of
clients will
receive and 60%
of clients will
complete the
survey
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